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Impact of Plasmodium falciparum malaria 
and intermittent preventive treatment 
of malaria in pregnancy on the risk of malaria 
in infants: a systematic review
Abel Kakuru1,2* , Sarah G. Staedke2, Grant Dorsey3, Stephen Rogerson4 and Daniel Chandramohan2
Abstract 
Background: Studies of the association between malaria in pregnancy (MiP) and malaria during infancy have pro-
vided mixed results. A systematic review was conducted to evaluate available evidence on the impact of Plasmodium 
falciparum malaria infection during pregnancy, and intermittent preventive treatment of malaria during pregnancy 
(IPTp), on the risk of clinical malaria or parasitaemia during infancy.
Methods: MEDLINE, EMBASE, Global Health, and Malaria in Pregnancy Library databases were searched from incep-
tion to 22 May 2018 for articles published in English that reported on associations between MiP and malaria risk 
in infancy. Search terms included malaria, Plasmodium falciparum, pregnancy, placenta, maternal, prenatal, foetal, 
newborn, infant, child or offspring or preschool. Randomized controlled trials and prospective cohort studies, which 
followed infants for at least 6 months, were included if any of the following outcomes were reported: incidence of 
clinical malaria, prevalence of parasitaemia, and time to first episode of parasitaemia or clinical malaria. Substan-
tial heterogeneity between studies precluded meta-analysis. Thus, a narrative synthesis of included studies was 
conducted.
Results: The search yielded 14 published studies, 10 prospective cohort studies and four randomized trials; all were 
conducted in sub-Saharan Africa. Infants born to mothers with parasitaemia during pregnancy were at higher risk 
of malaria in three of four studies that assessed this association. Placental malaria detected by microscopy or histol-
ogy was associated with a higher risk of malaria during infancy in nine of 12 studies, but only one study adjusted 
for malaria transmission intensity. No statistically significant associations between the use of IPTp or different IPTp 
regimens and the risk of malaria during infancy were identified.
Conclusion: Evidence of an association between MiP and IPTp and risk of malaria in infancy is limited and of variable 
quality. Most studies did not adequately adjust for malaria transmission intensity shared by mothers and their infants. 
Further research is needed to confirm or exclude an association between MiP and malaria in infancy. Randomized 
trials evaluating highly effective interventions aimed at preventing MiP, such as IPTp with dihydroartemisinin–pipe-
raquine, may help to establish a causal association between MiP and malaria in infancy.
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Background
In sub-Saharan Africa, an estimated 30 million preg-
nant women are at risk of Plasmodium falciparum infec-
tion every year [1]. In areas of moderate to high malaria 
transmission intensity, like most parts of sub-Saharan 
Africa, P. falciparum infection in pregnant women is 
usually asymptomatic because adults are usually par-
tially immune to malaria infection. However, P. falcipa-
rum infection during pregnancy can lead to placental 
malaria (PM). At delivery, 25% of pregnant women in 
sub-Saharan Africa were estimated to have PM detected 
by microscopy in 2007 [2]. Infection with P. falciparum 
during pregnancy has been associated with maternal 
morbidity such as maternal anaemia [3] and adverse birth 
outcomes including abortions, stillbirths, preterm deliv-
ery, and low birth weight [4–7].
The effects of P. falciparum infection during pregnancy 
on the infant may extend beyond the neonatal period [8]. 
Studies have shown that in utero fetal exposure to malaria 
antigens may negatively affect development of immunity 
to infectious diseases including malaria in the newborn 
[9–11]. Fetal exposure to P. falciparum antigens has been 
shown to induce malaria specific immune responses that 
are biased towards tolerance to malaria antigens [12–
14] while treatment of malaria in pregnancy (MiP) was 
shown to be associated with pro-inflammatory responses 
toward malaria specific antigens [15], suggesting that 
infants exposed to malaria in utero may have a higher 
risk of malaria during early childhood and treatment of 
MiP may improve anti-malarial immunity in infants. 
However, studies evaluating the association between MiP 
and malaria in infancy have shown mixed results. Some 
studies have reported an increased risk of clinical malaria 
or parasitaemia in infants born to mothers with placental 
malaria (PM) [16–18], while others have reported no dif-
ference in the risk of malaria in infants born to mothers 
with and without PM at delivery [19, 20]. One study has 
suggested that infants born to primigravid mothers with 
PM have a lower risk of malaria [21].
Intermittent preventive treatment of MiP (IPTp) with 
sulfadoxine–pyrimethamine (SP), remains one of the 
main interventions recommended by the World Health 
Organization (WHO) in areas of moderate to high 
malaria transmission intensity mainly to improve birth 
outcomes [22] despite widespread resistance of malaria 
parasites to antifolate drugs [23]. Although IPTp-SP 
still improves birth outcomes in settings with antifolate 
resistance [24], its impact on PM and maternal parasitae-
mia remains minimal [25, 26]. This continues to expose 
the fetus to malaria antigens which may negatively affect 
the health of the infant even after delivery [27]. Intermit-
tent preventive treatment has been shown to be associ-
ated with improved infant outcomes beyond delivery 
such as perinatal mortality [28] but the impact of IPTp 
on the risk of malaria during infancy is not well known. 
With available promising alternative drugs for IPTp such 
as dihydroartemisinin piperaquine (DP) which markedly 
reduce both the risk of malaria parasitaemia and inci-
dence of clinical malaria during pregnancy and reduce 
the prevalence of PM at delivery but does not clearly 
improve birth outcomes compared to IPTp-SP [25, 26, 
29], possible additional benefits of IPTp to the newborn 
including reducing the risk of malaria in infancy may 
have IPTp policy implications. Understanding the impact 
of IPTp on the risk of malaria in infants is important in 
order to maximize the benefits of malaria prevention in 
pregnancy.
To better understand the effect of maternal parasi-
taemia, PM, and IPTp on the risk of malaria in infants, 
which may have potential to guide policy on the choice 
of alternative drugs for IPTp, a systematic review was 
conducted to examine and summarize published studies 
evaluating the impact of P. falciparum parasitaemia in 
pregnancy and PM, and the effect of IPTp, on the risk of 
clinical malaria or parasitaemia in infants.
Methods
This systematic review was conducted following the 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analysis (PRISMA) guidelines [30]. The proto-
col for this systematic review was developed and regis-
tered with PROSPERO register (Registration number: 
CRD42018088869) prior to conducting the review.
Selection criteria
Original research studies were included if they were pub-
lished in English and evaluated associations between P. 
falciparum infection during pregnancy or IPTp and the 
risk of parasitaemia or incidence of malaria in infants 
born to HIV-uninfected pregnant women. Only rand-
omized controlled trials (RCTs) and prospective cohort 
studies in which infants were followed up for at least 
6  months were included. Studies involving only HIV-
exposed infants, animal studies, and studies of non-falci-
parum malaria were excluded.
Information sources and search strategy
MEDLINE, EMBASE, Global Health, and Malaria in 
Pregnancy (MiP) Library [31] databases were searched 
from inception to 22 May 2018. All review authors par-
ticipated in developing the search strategy and AK con-
ducted the search. MEDLINE, EMBASE and Global 
Health databases were searched via the Ovid interface 
using Medical Subject Headings (MeSH) of key search 
terms. The MiP library [31] was searched using key 
search terms, including malaria, Plasmodium falciparum, 
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falciparum malaria, pregnancy, placenta, maternal, foe-
tal, prenatal, utero, new-born, infant, child, offspring, 
and preschool. The search was limited to journal articles 
reporting human studies and published in the English 
language. Additional studies were identified by scruti-
nising reference lists of studies that met the inclusion 
criteria and relevant review articles. A bibliography of 
included studies was shared with other experts in the 
field of MiP to assess whether all the relevant articles had 
been retrieved.
Study selection
Lists of titles and abstracts of retrieved articles were 
exported to Endnote and duplicates were removed. 
Retrieved titles and abstracts were assessed for eligibility 
at the level of titles and abstracts by the corresponding 
author. Full articles and abstracts of potentially relevant 
articles and those where there was uncertainty about 
whether to include or exclude the article were retrieved 
and assessed for eligibility by two independent review-
ers (AK and DC). Where there was disagreement, it was 
resolved by discussing with the rest of the authors.
Data extraction process
Data were extracted by one reviewer (AK) and verified 
by a second reviewer (DC). A data extraction matrix in 
an Excel spreadsheet was developed and piloted prior to 
data extraction. The Excel spreadsheet included the fol-
lowing variables: author and year of publication, country 
where the study was done, study period (dates of field-
work), transmission intensity as measured by entomo-
logical inoculation rate, study design (considered RCT 
if IPTp was randomized, otherwise defined as an obser-
vational study), length of follow-up, follow-up schedule, 
study objectives, study population, sample size, long-last-
ing insecticide treated net (ITN) coverage among study 
participants, whether IPTp was given, type and frequency 
of IPTp regimen, whether maternal peripheral malaria 
parasitaemia was measured, timing of measurement 
of maternal peripheral malaria parasitaemia and how it 
was measured, PM detection, PM case definition, when 
and how clinical malaria or parasitaemia were detected 
in the infant, study outcomes, proportion of infants born 
to mothers with peripheral malaria parasitaemia or PM, 
adjustment for potential confounding factors, losses to 
follow-up, proportion of infants with outcomes of inter-
est, results including effect sizes with confidence inter-
vals and p-values, and study strengths and limitations. 
Disagreements between the two reviewers were resolved 
by discussion. Unresolved disagreements were settled by 
a third reviewer (either SS or GD or SR). Correspond-
ing authors of included studies were contacted by email 
for any missing or unclear information. Corresponding 
authors who did not respond to the first email con-
tact were contacted two more times and if they did not 
respond at the third contact, they were not contacted any 
further.
Assessment of risk of bias
The risk of bias in individual studies was assessed by two 
reviewers using the Newcastle–Ottawa quality assess-
ment scale for cohort studies [32], and the Cochrane 
Collaboration tool for randomized controlled trials [33]. 
Details of how the risk of bias was assessed in cohort 
studies were published in the systematic review protocol 
(PROSPERO Registration number: CRD42018088869). 
Studies were rated on the following categories: selection, 
comparability and outcome. For the selection category, 
studies were rated on the following items: representative-
ness of the exposed group (whether the exposed cohort 
was truly representative of the average from the commu-
nity), selection of the non-exposed group, measurement 
of the exposure (if the exposed and the unexposed were 
from the same community), and demonstration that the 
outcome was not present at the start of follow-up. For 
the comparability category, studies were assessed based 
on whether the study adjusted for malaria transmission 
or controlled for malaria prevention during pregnancy 
using IPTp or ITNs. In the outcome category, studies 
were rated on the following items: ascertainment of out-
come, whether follow-up was long enough for outcomes 
to occur (follow-up of at least 6 months was considered 
adequate), and completeness of follow-up (proportion of 
infants lost to follow, and whether characteristics of those 
lost to follow-up were reported). Each item in the selec-
tion and outcome categories was awarded a maximum 
of one point. The comparability category was awarded a 
maximum of two points. Studies were awarded a maxi-
mum of nine points. Studies that had a score of nine were 
rated as having medium risk of bias while those with a 
score of less than nine were rated as high risk.
Data synthesis
A systematic narrative synthesis of the included stud-
ies was conducted. A meta-analysis was not conducted 
because studies had substantial variation in the defini-
tion of malaria exposure during pregnancy, type of IPTp 
given, length of follow-up, and determination of primary 
outcome. Results were summarized using tables and in 
text. Tables with summary descriptions of study design, 
MiP exposure measurement, follow-up time, outcome 
measurement and results were generated. Studies were 
grouped in clusters according to the type of exposure 
(maternal peripheral malaria during pregnancy, or PM or 
IPTp), and outcome of interest (incidence of malaria in 
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infants, prevalence of malaria parasitaemia, time to first 
malaria parasitaemia or first episode of malaria).
Results
Study selection
Overall, 2084 titles and abstracts were identified and 
retrieved from searches of electronic databases. An addi-
tional two records were identified from searching lists 
and contacting experts in the field (Fig.  1). Of the 2086 
records, 461 duplicates were removed, and 1625 records 
were screened. Of these, 1582 records were excluded after 
review of the title and abstract, and 29 were excluded for 
various reasons after reviewing full text articles. Only 14 
articles were deemed to be eligible for inclusion in the 
systematic review.
Characteristics of included studies
All 14 studies were conducted in sub-Saharan Africa 
(Table  1); 10 prospective cohort studies and four RCTs. 
Of the 10 cohort studies, IPTp-SP was given in seven 
studies, and IPTp was not given in two [17, 34] because 
they were conducted before implementation of the WHO 
recommendation on IPTp. Malaria transmission data in 
form of entomological inoculation rate (number of infec-
tious mosquito bites per person per year) was reported 
in half of the included studies; 20.5 [35], 35 [18], 38 [16], 
2084 records retrieved from electronic databases
655 MEDLINE
485 EMBASE
702 Global Health
242 Malaria in Pregnancy Library
2086 records retrieved
14 full text arcles included for data synthesis
1625 tles and abstracts screened
461 duplicates excluded
43 full text arcles retrieved 
1582 records excluded 
1404 no report on associaon of interest
3 non-falciparum malaria
2 full text arcles not available
18 animal studies
63 case reports
92 review arcles
2 records retrieved from addional
sources
29 full text arcles excluded
20 no report associaon of interest
2 non-malaria outcome
1 HIV-exposed infants only
1 retrospecve cohort study
1 No measure of effect
1 No comparison group of interest
2 from Asia
1 of 2 arcles from one study in Benin 
Fig. 1 Study selection results
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50 [17], 257 [34], and 400 [19, 21]. The duration of fol-
low-up of infants ranged from 1 to 5 years. In 10 studies, 
infants were followed up from birth to 1 year of age [16, 
18–21, 34–38]. Maternal malaria exposure was deter-
mined by (1) microscopy (N = 5) [18, 36, 37, 39] or DNA 
PCR of maternal blood [40], (2) microscopy of placental 
blood only (N = 6) [17, 18, 21, 34, 35, 37], or (3) histol-
ogy of placental tissue (N = 5) [16, 19, 36, 40, 41]. Malaria 
infection during infancy was measured as malaria para-
sitaemia (prevalence of parasitaemia, N = 7; time to first 
parasitaemia, N = 4), and clinical malaria (incidence 
of clinical malaria, N = 5; time to first clinical malaria, 
N = 2). Malaria parasitaemia was assessed during weekly 
[35], fortnightly [21], or monthly [18, 37] routine visits. 
Clinical malaria was assessed by active surveillance in 
three studies [21, 35, 36] and by passive surveillance in 11 
of the studies [16–20, 34, 37–41]. ITN use in infants was 
not reported in half of the studies. In five studies, ITN 
use was reported as 100% [20, 41], 51% [21], 73% [19], 
and 95% [18]. In one study, 66% of infants were from fam-
ilies that owned at least an ITN at enrolment [35] while 
in another study, all infants did not have ITNs [34]. The 
Table 1 Characteristics of included studies
AL artemether lumefantrine, CQ chloroquine, IPTp intermittent preventive treatment of malaria in pregnancy, ISTp intermittent screening and treatment of malaria in 
pregnancy, MQ mefloquine, RCT randomized controlled trial, SP sulfadoxine–pyrimethamine
a Malaria detected in maternal blood by microscopy or PCR
b Placental malaria detected in placental blood by microscopy
c Placental malaria detected in placental tissue by histology
Author, year 
of publication. 
Country 
(references)
N Study design IPTp regimens Follow-up 
duration
Measures of malaria 
in pregnancy
Measures of malaria 
during infancy
Maternal 
 blooda
Placental 
 bloodb
Placental 
 histologyc
parasitaemia Clinical malaria
Tassi Yunga, 2018. 
Cameroon [34]
80 Cohort None 1 year ✓ ✓
Boudova, 2017. 
Malawi [40]
473 RCT SP vs CQ vs CQ 
prophylaxis
2 years ✓ ✓ ✓ ✓ ✓
Ruperez, 2016. 
Benin, Gabon, 
Tanzania, 
Mozambique 
[38]
4247 RCT SP vs MQ 1 year ✓
Sylvester, 2016. 
Tanzania [41]
206 Cohort Not reported 2 years ✓ ✓
De Beaudrap, 
2016. Uganda 
[37]
832 Cohort SP 1 year ✓ ✓ ✓
Awine, 2016. 
Ghana [19]
988 RCT SP vs ISTp-AL 1 year ✓ ✓
Apinjoh, 2015. 
Cameroon [36]
415 Cohort SP 1 year ✓ ✓ ✓ ✓
Ndibazza, 2013. 
Uganda [39]
2289 Cohort SP 5 years ✓ ✓
Borgella, 2013. 
Benin [18]
194 Cohort SP 1 year ✓ ✓ ✓ ✓
Asante, 2013. 
Ghana [20]
1855 Cohort SP 1 year ✓
Le Port, 2011. 
Benin [35]
550 Cohort SP 1 year ✓ ✓
Bardaji, 2011.
Mozambique 
[16]
997 RCT SP vs placebo 1 year ✓ ✓ ✓
Schwarz, 2008. 
Gabon [17]
527 Cohort None 2.5 years ✓ ✓
Mutabingwa, 
2005. Tanzania 
[21]
453 Cohort SP 1 year ✓ ✓
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median number of infants born to mothers with mater-
nal parasitaemia was 224 (range 28–236). The median 
number of infants born to mothers with PM detected by 
microscopy or histology was 59 (range 15–445). Out of 
11 studies which assessed association between PM and 
the risk of malaria in infants, there were three studies 
with ≥ 100 infants born to mothers with PM.
Association between maternal parasitaemia and the risk 
of malaria in infancy
The association between maternal parasitaemia and 
malaria risk in infancy was assessed in three cohort 
studies [18, 37, 39] and one RCT of IPTp-SP vs IPTp 
with chloroquine (CQ) vs CQ prophylaxis conducted in 
Malawi [40] (Table 2). In Malawi, infants born to moth-
ers with malaria parasitaemia detected during the 2nd 
or 3rd trimester had higher odds of parasitaemia com-
pared to infants born to mothers without parasitaemia 
during pregnancy, but the difference was not statistically 
significant [40]. In a cohort study conducted in Uganda, 
infants born to mothers with any parasitaemia detected 
by microscopy during pregnancy had a higher risk of par-
asitaemia during the first year of life compared to infants 
born to mothers without parasitaemia during pregnancy 
adjusted for gravidity, birth season, haemoglobin geno-
type, and residence (risk ratio [RR] 2.97; 95% confidence 
interval [CI] 1.37–6.42) [37]. In Benin [18], infants born 
to mothers having parasitaemia in the 3rd trimester had 
higher prevalence of parasitaemia (odds ratio [OR] 4.16; 
95% CI 1.64–10.54), shorter time to first clinical malaria 
(hazard ratio [HR] 3.19; 95% CI 1.59–6.38) and shorter 
time to first parasitaemia (HR 2.95; 95% CI 1.58–5.5) 
compared to those born to mothers without parasitae-
mia in the 3rd trimester after adjusting for birth season 
and residence near the lake (Table 2). In the same study, 
maternal parasitaemia detected during 1st or 2nd trimes-
ter was not associated with an increased risk of malaria 
during infancy [18]. In another cohort study conducted 
in Uganda, infants born to mothers with malaria parasi-
taemia at enrolment or at delivery had a higher incidence 
of clinical malaria during the first 5  years of life com-
pared to infants born to mothers without parasitaemia 
(HR 1.23; 95% CI 1.01–1.51) [39].
Association between placental malaria and risk of malaria 
in infants
Six studies evaluating the association between PM 
detected by microscopy only and the risk of malaria in 
infants produced mixed results (Table 3). The prevalence 
of parasitaemia was higher in infants born to mothers 
with PM detected by microscopy compared to those born 
to mothers without PM (RR 10.42; 95% CI 2.64–41.10) 
in a cohort study conducted in Uganda [37] while the 
prevalence of parasitaemia and clinical malaria tended 
to be lower in Benin [18] though this was not statisti-
cally significant (OR 0.72; 95% CI 0.25–2.11). Compared 
to infants born to mothers without PM, infants born to 
mothers with PM detected by microscopy had a shorter 
time to first parasitaemia in Cameroon [34], Benin [35] 
and Tanzania [21], and a shorter time to first clinical 
malaria in Gabon (HR 2.1; 95% CI 1.2–3.7) [17]. The only 
study that adjusted for malaria exposure among other 
confounding factors showed an association between PM 
detected by microscopy and time to first parasitaemia 
but only among infants resident in houses with ITNs (HR 
2.13; 95% CI 1.24–3.67) [35]. In another study conducted 
in Benin, there was no statistically significant association 
between PM detected by microscopy and time to first 
parasitaemia (OR 0.68; 95% CI 0.34–1.38) or time to first 
clinical malaria (HR 0.60; 95% CI 0.28–1.32) in infants 
[18].
Five studies evaluated associations between PM 
detected by histology and the risk of malaria in infancy 
(Table 4). Histology detected PM was associated with an 
increase in the odds of clinical malaria in Malawi (OR 
3.9; 95% CI 1.2–13.0) [40], Tanzania (OR 4.79; 95% 2.21–
10.38) [41], and Mozambique (OR 4.63; 95% CI 2.10–
10.24) [16] while one study in Cameroon did not find a 
statistically significant association between histologi-
cally detected PM and prevalence of malaria in infants 
(OR 0.72; 95% CI 0.40–1.28) [36]. Histologically detected 
PM was associated with a higher incidence of malaria in 
Malawi (unadjusted incident rate ratio [IRR] 2.3; 95% CI 
1.1–4.8) [40], but this was not observed in Ghana (IRR 
0.86; 95% CI 0.54–1.37) [19].
Impact of IPTp on the risk of malaria in infants
Four studies evaluated the impact of IPTp on the risk of 
malaria in infants (Table  5). Of these, three were RCTs 
and one was an observational study where some women 
received IPTp-SP and others received no IPTp. There 
was no significant difference in the incidence of malaria 
among infants born to mothers randomized to IPTp-MQ 
vs IPTp-SP (IRR 0.95; 95% CI 0.81–1.13) in a multicentre 
RCT conducted in Benin, Gabon, Tanzania, and Mozam-
bique [38] and among infants born to mothers rand-
omized to intermittent screening and treatment of MiP 
(ISTp) with artemether–lumefantrine (AL) vs IPTp-SP 
(IRR 0.94; 95% CI 0.68–1.59) conducted in Ghana [19]. 
In a cohort study conducted in Ghana, the risk of malaria 
was higher in infants born to mothers who did not 
receive IPTp compared to infants born to mothers who 
received IPTp-SP, but this difference was also not statisti-
cally significant [20]. In Mozambique, the odds of clinical 
malaria in infants born to mothers who were randomized 
to IPTp-SP were higher, but not statistically significantly 
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so, than in infants born to mothers randomized to pla-
cebo (OR 1.28; 95% CI 0.90–1.83) [16].
Assessment of risk of bias in individual studies
Risk of bias in individual studies was assessed using 
the Newcastle–Ottawa scale for observational studies 
(Table 6) and the Cochrane Collaboration tool for RCTs 
(Table  7). One study where IPTp was randomized was 
assessed using the Newcastle–Ottawa Scale for assess-
ing risk of bias in observational studies because the 
study only assessed an association between MiP (and 
Table 2 Association between maternal parasitaemia and malaria risk in infancy stratified by outcome measure
CI confidence interval, HIV human immunodeficiency virus, HR hazard ratio, IPTp intermittent preventive treatment of malaria in pregnancy, ITN insecticide treated net, 
NA not applicable number was imputed, NR not reported, OR odds ratio, RDT rapid diagnostic test, RR risk ratio, PCR polymerase chain reaction
Author, year 
of publication (refs.)
Timing 
of measurement 
of maternal 
parasitaemia
Method used 
to detect maternal 
parasitaemia
Exposure groups (n) Measure 
of association (95% 
CI), p value
Confounders adjusted 
for
Prevalence of parasitaemia
 Boudova, 2017 [40] 2nd and 3rd trimester PCR Unexposed (n = 184) Reference Maternal age, gestation 
age at delivery, IPTp 
arm
Exposed (n = 28) OR = 1.5 (0.5–4.4), 
p = 0.45
 De Beaudrap, 2016 
[37]
2nd and 3rd trimester Microscopy or RDT Unexposed (n = 626) Reference Gravidity, birth season, 
haemoglobin geno-
type, residence
Exposed (n = 198) RR = 2.97 (1.37–6.42), 
p = NR
 Borgella, 2013 [18] 1st trimester Microscopy Unexposed (n = NA) Reference Residence near the lake, 
birth seasonExposed (n = NA) OR = 1.12 (0.23–5.45), 
p = 0.89
2nd trimester Microscopy Unexposed (n = 142) Reference
Exposed (n = 52) OR = 0.87 (0.35–2.09), 
p = 0.75
3rd trimester Microscopy Unexposed (n = 121) Reference
Exposed (n = 73) OR = 4.16 (1.64–10.54), 
p = 0.003
Time to first parasitaemia
 Borgella, 2013 [18] 1st trimester Microscopy Unexposed (n = NA) Reference Residence near the lake, 
birth seasonExposed (n = NA) HR = 1.00 (0.42–2.39), 
p = 0.99
2nd trimester Microscopy Unexposed (n = 142) Reference
Exposed (n = 52) HR = 1.14 (0.62–2.12), 
p = 0.68
3rd trimester Microscopy Unexposed (n = 121) Reference
Exposed (n = 73) HR = 2.95 (1.58–5.50), 
p = 0.001
Time to first clinical malaria
 Borgella, 2013 [18] 1st trimester Microscopy Unexposed (n = NA) Reference Residence near the lake, 
birth seasonExposed (n = NA) HR = 0.97 (0.32–2.92), 
p = 0.95
2nd trimester Microscopy Unexposed (n = 142) Reference
Exposed (n = 52) HR = 1.15 (0.58–2.28), 
p = 0.70
3rd trimester Microscopy Unexposed (n = 121) Reference
Exposed (n = 73) HR = 3.19 (1.59–6.38), 
p = 0.001
Incidence of clinical malaria
 Ndibazza, 2013 [39] Baseline and delivery Microscopy Unexposed (n = 2053) Ref Maternal age, ITN pos-
session, parity, educa-
tion, social economic 
status, residence, 
mother’s HIV status
Exposed (n = 236) HR = 1.23 (1.01–1.51), 
p = 0.04
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not IPTp regimens) and the risk of clinical malaria or 
parasitaemia in the infant [40]. All cohort studies had 
a representative exposed cohort, selected the non-
exposed comparison group adequately and measured 
malaria exposure during pregnancy, and demonstrated 
that the outcome was not present at the beginning of 
follow-up. Most of the studies adjusted for IPTp and 
ITN use but only two studies [20, 35] adjusted for 
malaria exposure. In three of the studies, the number of 
participants lost to follow-up or the reasons for losses 
to follow-up were not reported [16, 36, 41]. Three stud-
ies had > 20% losses to follow-up [17, 36, 40]. The over-
all risk of bias in cohort studies was rated as high in 
nine studies [17, 18, 21, 34, 36, 37, 39–41] and medium 
in two studies [20, 35]. In all the RCTs, allocation con-
cealment was adequate, and no trial was stopped before 
completion. Overall, the risk of bias in all three RCTs 
was low.
Discussion
This systematic review assessed evidence evaluating the 
associations between MiP or IPTp and the risk of malaria 
infection or illness during infancy. Overall, the avail-
able evidence is of insufficient quality to confirm or rule 
out an association between maternal malaria infection 
and the risk of malaria during infancy. Most studies had 
small numbers of exposed infants and failed to control 
for possible confounding by malaria transmission inten-
sity shared between mothers and their infants. Only one 
study that examined the association between malaria in 
pregnancy and the risk of malaria in infants controlled for 
malaria transmission at the level of the household [35]. 
In this study, time to first parasitaemia in infants born 
to mothers with PM was shorter in those who lived in 
households with ITNs, than in those living in households 
without ITNs. It is possible that household use of ITNs 
reflects underlying malaria transmission intensity, with 
households exposed to higher transmission more likely to 
Table 3 Association between  placental malaria detected by  microscopy and  the  risk of  malaria in  infancy stratified 
by outcome
CI confidence interval, HIV human immunodeficiency virus, HR hazard ratio, IPTi intermittent preventive treatment of malaria in infancy, ITN insecticide treated net, NR 
Not reported, OR odds ratio, PM placental malaria, RR risk ratio
a Placental malaria detected by microscopy or PCR; PM Lo, placental malaria with < 25 infected erythrocytes/µL; PM Hi, placental malaria with > 25 infected 
erythrocytes/µL
Country, year of publication (ref) PM exposure group (n) Measure of association (95% CI), 
p-value
Confounders adjusted for
Prevalence of parasitaemia
 De Beaudrap, 2016 [37] Unexposed (475) Reference Gravidity, maternal age, residence, level of 
education, season, maternal HIV status, 
ITN use
Exposed (15) RR = 10.42 (2.64–41.10), p = NR
 Borgella, 2013 [18] Unexposed (154 Reference Residence near the lake, birth season
Exposed (36) OR = 0.72 (0.25–2.11), p = 0.55
Time to first parasitaemia
 Tassi Yunga,  2018a [34] No PM (36) Reference Gravidity, birth season Hb genotype, 
residencePM Lo (18) HR = 2.6 (1.3–4.8)
PM Hi (18) HR = 1.5 (0.7–3.7)
 Borgella, 2013 [18] Unexposed (154) Reference Residence near the lake, birth season
Exposed (36) HR = 0.68 (0.34–1.38), p = 0.29
 Le Port, 2011 [35] Unexposed (485) Reference Unadjusted
Exposed (59) HR = 1.62 (1.08–2.43), p = 0.02
 Le Port, 2011 [35] Unexposed, had ITN (321) Reference Exposure to anopheles, season, antenatal 
care, severe anaemiaExposed, had ITN (34) HR = 2.13 (1.24–3.67), p < 0.01
Unexposed, no ITN (158) Reference
Exposed, no ITN (25) HR = 1.18 (0.60–2.33), p = 0.62
 Mutabingwa, 2005 [21] Unexposed (384) Reference Gravidity, residence, transmission season 
at birth, and bed net usageExposed (69) HR = 1.41 (1.01–1.99), p = NR
Time to first clinical malaria
 Borgella, 2013 [18] Unexposed (154) Reference Residence near the lake, birth season
Exposed (36) HR = 0.60 (0.28–1.32), p = 0.21
 Schwarz, 2008 [17] Unexposed (477) Reference Gravidity, residence, birth season, IPTi, bed 
net useExposed (50) HR = 2.1 (1.2–3.7), p = NR
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use ITNs, and mothers and infants in such households at 
higher risk of malaria. However, secondary data analysis 
of the study did not find an association between PM and 
the risk of subsequent clinical malaria episodes [42]. This 
suggests that the effect of PM on the risk of malaria in 
infants wanes over time.
Majority of the studies included in this review showed 
an increased risk of clinical malaria or parasitaemia 
in infants born to mothers with maternal peripheral 
parasitaemia [37, 39], infants born to mothers with 
PM detected by microscopy [17, 21, 34, 35, 37] and in 
infants born to mothers with PM detected by histology 
[16, 40, 41]. These results could possibly be explained 
by confounding due to differences in malaria transmis-
sion intensity. Infants born to mothers with maternal 
peripheral parasitaemia during pregnancy or PM at 
delivery could be at higher risk of clinical malaria or 
parasitaemia because they live in an environment with 
higher risk of malaria transmission just like their moth-
ers [43].
Table 4 Association between  placental malaria detected by  histology and  the  risk of  malaria in  infancy stratified 
by outcome
CI confidence interval, IPTp intermittent preventive treatment of malaria in pregnancy, IRR, incident rate ratio, ITN insecticide treated net, NR not reported, OR odds 
ratio
Country, year 
of publication (ref)
Placental malaria 
exposure group (n)
Measure of association (95% CI), p-value Confounders adjusted for
Clinical malaria
 Boudova, 2017 [40] Unexposed (184) Reference Maternal age, gestation age at delivery, IPTp arm
Exposed (67) OR = 3.9 (1.2–13.0), p = 0.03
 Boudova, 2017 [40] Unexposed (184) Reference Unadjusted
Exposed (67) IRR = 2.3 (1.1–4.8), p = NR
 Sylvester, 2016 [41] Unexposed (165) Reference Gravity, season of birth, infant birth weight, maternal age
Exposed (41) OR = 4.79 (2.21–10.38), p < 0.05
 Awine, 2016 [19] Unexposed (484) Reference ITN use, gender, social economic status, living near an 
irrigated area, infant age, maternal baseline parasitae-
mia
Exposed (202) IRR = 0.86 (0.54–1.37), p = 0.52
 Apinjoh, 2015 [36] Unexposed (n = 237) Reference Not indicated
Exposed (n = 166) OR = 0.72 (0.40–1.28), p = 0.26
 Bardaji, 2011 [16] Unexposed (424) Reference Residence near the lake, birth season
Past infection (321) OR = 3.06 (1.94–4.82), p < 0.001
Acute infection (42) OR = 4.63 (2.10–10.24), p < 0.001
Chronic infection (82) OR = 3.95 (2.07–10.24), p < 0.001
Prevalence of parasitaemia
 Boudova, 2017 [40] Unexposed (184) Reference Maternal age, gestation age at delivery, IPTp arm
Exposed (67) OR = 2.5 (1.0–6.3), p = 0.06
Table 5 Impact of IPTp on the risk of malaria in infancy
AL artemether lumefantrine, CI confidence interval, IPTp intermittent preventive treatment of malaria in pregnancy, IRR incident rate ratio, ISTp intermittent screening 
and treatment of malaria in pregnancy, ITN insecticide treated nets, HR hazard ratio, MQ mefloquine, SP sulfadoxine–pyrimethamine
Author, year of publication Randomized
Y/N
IPTp arm (n) Measure of association (95% 
CI), p-value
Confounders adjusted for
Ruperez,, 2016 [38] Yes IPTp-SP (1432) Reference Country
IPTP-MQ (2815) IRR = 0.95 (0.81–1.13), p = 0.60
Awine, 2016 [19] Yes IPTp-SP (495) Reference Gender, social economic status, residence, irrigated 
area, season, ITN use, baseline parasitaemia, 
maternal haemoglobin
ISTp-AL (493) IRR = 0.94 (0.68–1.59), p = 0.76
Asante, 2013 [20] No IPTp-SP (1755) Reference Unadjusted
No IPTp (97) HR = 1.23 (0.93–1.59), p = 0.15
Bardaji, 2011 [16] Yes Placebo (500) Reference Unadjusted
IPTp-SP (497) OR = 1.28 (0.90–1.83), p = 0.17
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Because it would not be ethical and feasible to ran-
domize pregnant women to exposure to MiP, alterna-
tive study designs are needed, such as randomising 
pregnant women to IPTp interventions with different 
efficacies and comparing the risks of parasitaemia and 
clinical malaria in the different sets of infants born to 
mothers who received different IPTp interventions. In 
this systematic review, three RCTs which evaluated the 
association between IPTp and the risk of malaria dur-
ing infancy showed no difference in the risk of malaria 
among infants born to mothers who received IPTp-
MQ vs IPTp-SP [38], ISTp-AL vs IPTp-SP [19], and 
IPTp-SP vs placebo [16]. These studies were possibly 
limited by the failure of the alternative intervention to 
significantly reduce the burden of malaria especially 
PM during pregnancy [44, 45]. The prevalence of PM 
was not significantly different among mothers rand-
omized to IPTp-MQ (4.6%) compared to IPTp SP (5.4%, 
p = 0.19) in the multicentre trial [44], and was similar 
among mothers randomized to IPTp-SP (24.5%) com-
pared to ISTp-AL (24.2%) in the Ghana trial [45]. In the 
Mozambique trial, the prevalence of any PM detected 
by histology or microscopy was similar among moth-
ers on IPTp-SP (52%) or placebo (52%) [46]. Although 
in the same trial, the prevalence of PM detected by 
microscopy was higher among women on placebo 
(14%) compared to women on IPTp-SP (7%) [46], the 
risk of clinical malaria did not differ among infants 
born to mothers on the two IPTp arms [16]. This could 
possibly be due to few malaria outcomes during infancy 
Table 6 Assessment of risk of bias for observational studies using the Newcastle–Ottawa scale
REC representativeness of the exposed cohort, SNEC selection of the non-exposed cohort ME measurement of exposure to malaria during pregnancy, DON 
demonstration that the outcome of interest was not present at the start of the study, AME adjusted for malaria transmission exposure AI adjusted for IPTp or 
insecticide treated net use, AO assessment of the outcome FL follow-up long enough for outcome to occur, CF completeness of follow-up
–, score of zero; *, score of one
Author, year of publication (ref) Selection Comparability Outcome Total Overall risk of bias
REC SNEC ME DON AME AI AO FL CF
Tassi Yunga, 2018 [34] * * * * – – * * * 7 High
Boudova,, 2017 [40] * * * * – * * * – 7 High
Sylvester, 2016 [41] * * * * – – * * – 6 High
De Beaudrap, 2016 [37] * * * * – * * * * 8 High
Apinjoh, 2015 [36] * * * * – – * * – 6 High
Ndibazza, 2013 [39] * * * * – * * * * 8 High
Borgella, 2013 [18] * * * * – * * * * 8 High
Asante, 2013 [20] * * * * * * * * * 9 Medium
Le Port, 2011 [35] * * * * * * * * * 9 Medium
Schwarz, 2008 [17] * * * * – * * * – 7 High
Mutabingwa, 2005 [21] * * * * – * * * * 8 High
Table 7 Assessment of  risk of  bias in  randomized trials comparing the  risk of  malaria among  infants who received 
different IPTp regimens
NR not reported
Criterion Studies
Ruperez, 2016 [38] Awine, 2016 [19] Bardaji, 
2011 
[16]
Allocation concealment Yes Yes Yes
Trial stopped early No No No
Participants blinded No No Yes
Study staff blinded No No Yes
Infant malaria assessed blinded Yes Yes Yes
Proportion of infants lost to follow-up 972/4247 (22.9%) NR NR
Overall risk of bias Low Low Low
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(there were 135 first clinical malaria episodes during 
follow-up), which limited the power of the study.
There is currently a promising alternative drug combi-
nation for IPTp, which substantially reduces the burden 
of malaria during pregnancy including PM compared to 
SP. Although SP remains the drug recommended by the 
WHO for IPTp [22], its effectiveness is affected by wide-
spread antifolate resistance [47]. In East Africa, IPTp-
DP has been shown to markedly reduce the incidence 
of clinical malaria and the prevalence of parasitaemia 
during pregnancy, and the prevalence of PM at delivery 
compared to IPTp-SP [25, 26, 29]. One study has evalu-
ated the impact of IPTp-DP on malaria during infancy 
in Uganda. In this randomized controlled trial, which 
examined infants receiving DP for malaria prevention, 
the incidence of malaria during the first 2 years of life was 
higher in infants born to pregnant women who received 
IPTp-DP (given monthly) than in those born to women 
who received IPTp-SP (given every 2 months). This effect 
was magnified in female infants [48]. The reason for this 
finding is unclear, but may be due to lower blood levels 
of piperaquine, which were observed in female infants 
born to mothers who received IPTp-DP [48]. Lower pipe-
raquine levels have been associated with a higher risk 
of malaria in children taking DP for malaria prevention 
[49], but the reason why female infants born to moth-
ers receiving IPTp-DP would have lower levels of pipe-
raquine is unknown.
Several studies have suggested immune tolerance [9, 
12, 14, 50] as one of the potential mechanisms for the 
observed association between MiP and the risk of malaria 
in infants. Evidence from laboratory studies shows that in 
utero exposure to malaria antigens is associated with a 
bias of fetal immune responses to P. falciparum specific 
[12–14] or non-malaria specific [12, 50] antigens towards 
anti-inflammatory responses suggesting that exposure 
to malaria in utero may not only affect development of 
malaria specific immunity in the fetus but may also affect 
non-malaria specific immunity. Indeed, one study has 
reported an increased risk of non-malaria febrile illnesses 
in infants born to mothers with PM compared to infants 
born to mothers without PM [51]. Also, PM has been 
associated with a reduced maternal–fetal transfer of anti-
bodies to P. falciparum [52, 53], but this was not associ-
ated with an increased risk of malaria in infants [52, 53].
This systematic review had several limitations. Sub-
stantial heterogeneity in included studies was found. 
Studies varied in the duration of follow-up, detection of 
malaria exposure during pregnancy, and approaches to 
measuring the outcome in infants and to data analysis. 
Also, important raw data like the number of malaria epi-
sodes in each malaria exposure group during pregnancy 
was not presented in majority of the studies. Majority 
of studies included in this systematic review used PM 
as a proxy measure of MiP. PM may not be a good proxy 
measure of MiP because some mothers with peripheral 
malaria parasitaemia may clear the parasites especially 
with highly efficacious IPTp drugs. However, majority 
of the included studies used IPTp-SP, which is not highly 
effective at clearing parasites [54]. Only studies published 
in English were included in this systematic review. This 
could have led to missing out on potential studies pub-
lished in English. However, a literature search not limit-
ing the language to English did not yield any such studies. 
The search strategy was also limited to only published 
studies. This could have limited the number of studies 
with null findings, which are less likely to be published.
Conclusion
The results of this systematic review suggest that there 
is insufficient evidence to confirm or exclude a causal 
association between MiP and the risk of malaria during 
infancy. Also, evidence on the impact of IPTp on the risk 
of malaria in infancy is inconclusive. There is need to bet-
ter understand the association between MiP and malaria 
in infants in order to minimize the effects of MiP on 
malaria during infancy. Future studies of new IPTp inter-
ventions should consider not only evaluating the impact 
of IPTp on birth outcomes but also the potential impact 
of the intervention on the risk of clinical malaria or para-
sitaemia in infancy. This could have important policy 
implications on the choice of future drugs for IPTp.
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